Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.

Cancer research - 1 Sept 2013

Oike Takahiro, Ogiwara Hideaki, Tominaga Yuichi, Ito Kentaro, Ando Osamu, Tsuta Koji, Mizukami Tatsuji, Shimada Yoko, Isomura Hisanori, Komachi Mayumi, Furuta Koh, Watanabe Shun-Ichi, Nakano Takashi, Yokota Jun, Kohno Takashi

Abstract excerpt

The occurrence of inactivating mutations in SWI/SNF chromatin-remodeling genes in common cancers has attracted a great deal of interest. However, mechanistic strategies to target tumor cells carrying such mutations are yet to be developed. This study proposes a synthetic-lethality therapy for treating cancers deficient in the SWI/SNF catalytic (ATPase) subunit, BRG1/SMARCA4. The strategy relies upon inhibition of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Cellular Senescence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Lethal

Share to Immunoenzyme Techniques

Share to Kinesins

Share to Oncogene Proteins, Fusion

Share to Receptor Protein-Tyrosine Kinases

Share to Receptors, Mitogen

Source

Identifiers

PMID: 23872584
DOI: 10.1158/0008-5472.CAN-12-4593

Genes

SMARCA4
ALK
DDR2
EGFR
FGFR1
SMARCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.PMID 23872584Read ↗

In-Depth Characterization and Validation in <i>BRG1</i> -Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin RemodelingSemantic proximity Read ↗

Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer developmentSemantic proximity Read ↗

Inhibition of a Selective SWI/SNF Function Synergizes with ATR Inhibitors in Cancer Cell KillingSemantic proximity Read ↗

Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell KillingSemantic proximity Read ↗

The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.Semantic proximity Read ↗

The BRG1 ATPase of Human SWI/SNF Chromatin Remodeling Enzymes as a Driver of CancerSemantic proximity Read ↗

Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid LeukemiaSemantic proximity Read ↗

Targeting of BRM Sensitizes BRG1 -Mutant Lung Cancer Cell Lines to RadiotherapySemantic proximity Read ↗

BRG1/SMARCA4 Inactivation Promotes Non–Small Cell Lung Cancer Aggressiveness by Altering Chromatin OrganizationSemantic proximity Read ↗

Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.Semantic proximity Read ↗

Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex InactivationSemantic proximity Read ↗

BRM: the core ATPase subunit of SWI/SNF chromatin-remodelling complex—a tumour suppressor or tumour-promoting factor?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.